English
Chinese (Simplified)
About Us
INmuneBio
INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
Products
INKmune™
INKmune is a biologic delivery system that allows us to deliver the missing S1 (priming signal) to the patient’s resting NK cells. INKmune is delivered by a simple IV infusion.
Products
INB03
INB03 is a checkpoint inhibitor that targets myeloid-derived suppressor cells (MDSC) in the tumor microenvironment that produce an immunosuppressive shield that prevents the patient’s immune system from attacking the cancer.
Stay Tuned
Latest News
- Apr 17, 2019 INmune Bio Presenting Poster at the Neuroimmunology Drug Development Summit
- Apr 09, 2019 INmune Bio Co-Founder and CEO to Speak at Cambridge Healthtech Institute’s 10th Annual Inflammation Inhibitors Conference
- Apr 08, 2019 INmune Bio Announces Poster Presentation with New Data Regarding Neurodegenerative Disease Drug Candidate, XPro1595, at The European Conference on Neuroinflammation
| Have a Question? 858 964 3720 |
| Email Us dmoss@inmunebio.com |
| Opening Hours M - F 8am to 5pm PST |